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Introduction
Hereditary predisposition to breast cancer can be attrib-
uted to germline mutations in the BRCA1 or BRCA2
breast cancer susceptibility genes [1]. Germline mutations
in the BRCA1 and BRCA2 genes are associated with the
development of breast and ovarian cancers [2]. BRCA2 is
associated the development of breast cancer in both
women and men [3], and a moderate increased risk for the
development of ovarian cancer.
Zabludoff  et al [4] investigated the tissue distribution of
Brca1 mRNA in adult mouse tissues and reported that
Brca1 mRNA levels were most abundant in the testis and
the ovary. They also found that high level Brca1 mRNA
expression in the testis of mice was detected in meiotic cells
and postmeiotic round spermatids and, in contrast, little or
no Brca1 mRNA was expressed in premeiotic germ cells. A
low level of Brca1 mRNA was also detected in Sertoli cells.
Blackshear et al [5], on the contrary, demonstrated in the
mouse that Brca1 and Brca2 mRNA are expressed in mitotic
spermatogonia in addition to early meiotic prophase sperma-
tocytes; Sertoli cells and Leydig interstitial cells were found
consistently negative for Brca1 and Brca2 transcripts. In the
normal mouse adult ovary, Brca1 and Brca2 transcripts were
localized specifically to granulosa cells, thecal cells and
oocytes of developing follicles as well as luteal cells of
recently formed corpora lutea and surface epithelium.
Considering these results, we further investigated the
presence of human BRCA1 and BRCA2 proteins in an
ovotestis by immunochemical analysis with a different
panel of antibodies against BRCA1 and BRCA2.
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GST = glutathione-S-transferase.
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Abstract
BRCA1 and BRCA2 breast cancer susceptibility genes encode proteins, the normal cellular functions
of which are complex and multiple, and germ-line mutations in individuals predispose both to breast
and to ovarian cancer. There is nevertheless substantial evidence linking BRCA1 and BRCA2 to
homologous recombination and DNA repair, to transcriptional control and to tissue proliferation. There
is controversy regarding the localization of BRCA1 and BRCA2 proteins to either nucleus or
cytoplasm and whether the expression is present in premeiotic germ cells or can still be expressed in
mitotic spermatogonia. We report herein an immunohistochemical study of BRCA1 and BRCA2
distribution in a rather unusual tissue (an ovotestis), which addresses this issue.
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Figure 1
Immunohistochemical localization of BRCA1 and BRCA2 with formalin-fixed and paraffin sections in an ovotestis. (a) Hematoxylin eosin saffron
(HES) histology of the ovotestis demonstrating testicular tissue with seminiferous cords (triangle), adjacent to ovarian tissue with primordial follicles
(arrow) (×200). For BRCA1 protein: (b) K-18 antibodies showed cytoplasmic staining of oocytes (arrowhead) surrounded by follicule primordial
and cytoplasmic staining of male germ cells (arrow) in seminiferous cords identified by the presence of Sertoli cells inside (×220); (c) 8F7
antibodies showed predominantly nuclear stainings of Sertoli cells (asterisk) and of oocytes (arrowhead), and cytoplasmic staining was also
exhibited in the oocytes (×450); (d) 17F8 antibodies showed exclusive nuclear staining of Sertoli cells (arrow) (×470); (e) 17F8 antibodies
showed cytoplasmic staining of oocytes (arrow) (×315); (f) 66046N antibodies showed cytoplasmic staining of oocytes (arrowhead) (×540); and
(g) 66036N antibodies showed cytoplasmic staining of male and female germ cells, and slight nuclear staining in Sertoli cells in the tube (asterisk)
(×385). For BRCA2 protein: (h) 66066E antibodies showed cytoplasmic staining of Sertoli cells (arrowhead) and oocytes (asterisk) (×545); and
(i) 3E6 antibodies showed low cytoplasmic staining of Sertoli cells (asterisk) and female germ cells (arrowhead) (×660).Materials and methods
True hermaphroditism is a rare cause of atypical genitalia
that presents significant diagnostic and management
challenges. The patient (male, 6 months old, karyotype of
46, XX; analysis of a sex-determining region of the Y
chromosome [SRY] was negative) had a testis on the left
side and an ovotestis on the right side. Hematoxylin eosin
saffron (HES) demonstrated male and female compart-
ments of the ovotestis (Fig. 1a). This paper presents our
laboratory findings concerning the BRCA1 and BRCA2
protein expression in this particular gonad. All antibodies
are described in Table 1.
Results and discussion
The specificity of the polyclonal antibody against BRCA1
(K-18) has been demonstrated elsewhere for BRCA1
[6,7], ascertained by Western blotting, and the 220kDa
band corresponding to BRCA1 was detected in both
HBL-100 and MCF-7 breast cell lines. Moreover, other
major bands appeared around 100kDa in the two cell
lines, which may correspond to different variants to
BRCA1 [7,8].
Chen et al [9] previously reported that the monoclonal
antibodies anti-BRCA1 8F7 and 17F8 always exhibited a
nuclear staining pattern in breast epithelial cells. Lee et al
[10] had already reported that nuclear staining of the
BRCA1 protein with 17F8 monoclonal antibody was also
seen in tumor cells that were not of breast or ovarian
origin. Wilson et al [11] also reported recently that 17F8
antibody detected BRCA1 nuclear and cytoplasmic stain-
ings in breast specimens according to antibody concen-
tration. We have also reported a nuclear staining pattern
with different tissues, notably in child mammary gland
[12] and in lung from a fetus at 19 weeks’ gestation [13],
with the 8F7 and 17F8 anti-BRCA1 monoclonal antibod-
ies raised against a glutathione-S-transferase
(GST)–BRCA1 fusion protein containing amino acids
encoded by a 3¢ portion of BRCA1 exon 11 and by a 5¢
portion of BRCA1 exon 11, respectively. These antibod-
ies seemed to remain more specific, and they exhibited
nuclear staining.
We used anti-BRCA1 antibodies raised against amino
acids 768–793 (66046N) and amino acids 1847–1863
(66056N). Characterization of these antibodies in MCF-7
human breast tumor cell lysates by Western blotting (data
not shown) resulted in the detection of a 220kDa band
corresponding to BRCA1, and one other band around
100kDa that may correspond to the BRCA1 protein
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Table 1
Specificity of the primary antibodies used, and corresponding subcellular localization and degree of staining observed for
ovotestis
Staining of ovotestis
Male germ cells
Antibodies Specificities Sources and Sertoli cells Female germ cells
Anti-BRCA1
K-18* hBRCA1 (aa 70–89) Santa Cruz Biotechnologies Cyt. (+) Cyt. (+)
8F7† Fusion protein GST–hBRCA1 GeneTex N (+) Cyt. (+), N (+)
(aa 341–748)
17F8† Fusion protein GST–hBRCA1 GeneTex N (+) Cyt. (+)
(aa 762–1315)
66036N* hBRCA1 (aa 2–20) Pharmingen Cyt. (+), N (+) Cyt. (+)
66046N* hBRCA1 (aa 768–793) Pharmingen Cyt. (+) Cyt. (+)
66056N* hBRCA1 (aa 1847–1863) Pharmingen Cyt. (+) Cyt. (++)
Anti-BRCA2
66066E* hBRCA2 (aa 1323–1346) Pharmingen Cyt. (+) Cyt. (+)
66076E* hBRCA2 (aa 2586–2600) Pharmingen Cyt. (+) Cyt. (+)
5F6 (clone 1H3)† Fusion protein GST–hBRCA2 GeneTex Cyt. (+) Cyt. (+), N (+)
(aa 2336–2478)
3E6† Fusion protein GST–hBRCA2 GeneTex Cyt. (+) Cyt. (+)
(aa 188–563)
*Rabbit polyclonal antibodies and †mouse monoclonal antibodies. aa, Amino acid; Cyt., cytoplasm; N, nuclear; (+) intensive; (++), very intensive.missing exon 11. The 66036N antibodies elicited against
amino acids 2–20 of human BRCA1 recognized a 220kDa
BRCA1 protein in HBL-100 breast cell lysates [14].
The antibody for BRCA2 (66066E) recognizes epitopes
between amino acids 1323–1346 of human BRCA2. The
antibody 66076E recognizes epitopes between amino
acids 2586–2600. Antibodies were purchased from
PharMingen (San Diego, CA, USA) and tested by
Western blotting in HBL-100 human breast cells to
ensure they recognized the 390kDa BRCA2 protein. Both
BRCA2 antibodies also cross-reacted with smaller pro-
teins, which could be degradation products.
The 3E6 and 5F6 anti-BRCA2 monoclonal antibodies
were generated using two bacterially expressed and puri-
fied GST–BRCA2 fusion proteins, containing amino
acids 188–563 and 2336–2478 as antigens, respec-
tively [15]. Using the 3E6 antibodies, we detected a
protein of 390kDa, in MCF-7 human tumor breast cell
lysates, which corresponds to the predicted size of the
3418 amino acid BRCA2 sequence. We also detected,
in CCL 221 colorectal adenocarcinoma cell lysates, a
single band at 390kDa using the 5F6 antibodies (data
not shown).
As shown in Fig. 1 and Table 1 for the BRCA1 protein
expression study with K-18 antibodies, only cytoplasmic
stainings in male germ cells and in oocytes were obtained
(Fig. 1b). Predominant nuclear stainings of Sertoli cells
and oocytes were obtained with 8F7 antibodies (Fig. 1c),
and cytoplasmic staining of oocytes was also exhibited.
Staining patterns with 17F8 antibodies varied from exclu-
sively nuclear staining in Sertoli cells (Fig. 1d) to exclu-
sively cytoplasmic staining in oocytes (Fig. 1e).
Exclusively cytoplasmic staining was seen in male and
female germ cells with 66046N (Fig. 1f) and 66056N
antibodies (data not shown). In contrast, cytoplasmic
staining with 66036N antibodies (Fig. 1g) was exhibited
in male and female germ cells, and low nuclear staining
was found in Sertoli cells.
For BRCA2 protein expression in Sertoli cells and
oocytes, exclusively cytoplasmic staining was seen with
66066E antibodies (Fig. 1h). Cytoplasmic staining (data
not shown) was exhibited with 66076E antibodies in
oocytes and in male germ cells. Cytoplasmic staining was
obtained in male and female compartments with 3E6 anti-
bodies (Fig. 1i). With 5F6 antibodies (data not shown),
exclusively cytoplasmic staining was obtained for BRCA2
protein in the male compartment, and low intensive
nuclear and cytoplasmic stainings were obtained in
oocytes and follicles.
The differences of staining patterns for the same protein in
the same tissue may be explained by the choice of the
antibodies. The monoclonal antibodies raised against
GST–BRCA1 or GST–BRCA2 fusion proteins seem more
specific than antibodies raised against a 20 amino acid
peptide.
Conclusion
In conclusion, we show using different antibodies that
BRCA1 proteins, like BRCA2, are widely expressed in two
varieties of non-embryogenic human tissues associated
with the cell cycle. BRCA1 and BRCA2 proteins are
expressed during growth and differentiation in the ovary.
Moreover, they are expressed beyond the spermatogene-
sis. This is consistent with proposed functions for BRCA1
and BRCA2 genes.
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